Clinical Trials Browser

INDUSTRY × Interventional × ozanimod × Clear all

NCT04639115 2022-06-14

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

Phase 1 Completed

Digestive System Diseases, Liver Diseases, Lymphoma, Follicular